MX2024003262A - Composiciones y metodos para producir poliribonucleotidos circulares. - Google Patents

Composiciones y metodos para producir poliribonucleotidos circulares.

Info

Publication number
MX2024003262A
MX2024003262A MX2024003262A MX2024003262A MX2024003262A MX 2024003262 A MX2024003262 A MX 2024003262A MX 2024003262 A MX2024003262 A MX 2024003262A MX 2024003262 A MX2024003262 A MX 2024003262A MX 2024003262 A MX2024003262 A MX 2024003262A
Authority
MX
Mexico
Prior art keywords
compositions
methods
producing circular
circular polyribonucleotides
producing
Prior art date
Application number
MX2024003262A
Other languages
English (en)
Spanish (es)
Inventor
Ki Young Paek
Boer Alexandra Sophie De
Vadim Dudkin
Jennifer A Nelson
Original Assignee
Flagship Pioneering Innovations Vi Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Flagship Pioneering Innovations Vi Llc filed Critical Flagship Pioneering Innovations Vi Llc
Publication of MX2024003262A publication Critical patent/MX2024003262A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y113/00—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13)
    • C12Y113/12—Oxidoreductases acting on single donors with incorporation of molecular oxygen (oxygenases) (1.13) with incorporation of one atom of oxygen (internal monooxygenases or internal mixed function oxidases)(1.13.12)
    • C12Y113/12005—Renilla-luciferin 2-monooxygenase (1.13.12.5), i.e. renilla-luciferase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/532—Closed or circular
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
MX2024003262A 2021-09-17 2022-09-16 Composiciones y metodos para producir poliribonucleotidos circulares. MX2024003262A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163245354P 2021-09-17 2021-09-17
PCT/US2022/043808 WO2023044006A1 (en) 2021-09-17 2022-09-16 Compositions and methods for producing circular polyribonucleotides

Publications (1)

Publication Number Publication Date
MX2024003262A true MX2024003262A (es) 2024-06-19

Family

ID=83688860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003262A MX2024003262A (es) 2021-09-17 2022-09-16 Composiciones y metodos para producir poliribonucleotidos circulares.

Country Status (15)

Country Link
US (2) US12338474B2 (cg-RX-API-DMAC7.html)
EP (2) EP4464783A3 (cg-RX-API-DMAC7.html)
JP (1) JP2024534428A (cg-RX-API-DMAC7.html)
KR (1) KR20240099185A (cg-RX-API-DMAC7.html)
CN (1) CN118234867A (cg-RX-API-DMAC7.html)
AR (1) AR127073A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022346861A1 (cg-RX-API-DMAC7.html)
CA (1) CA3232635A1 (cg-RX-API-DMAC7.html)
DK (1) DK4271818T3 (cg-RX-API-DMAC7.html)
ES (1) ES2994006T3 (cg-RX-API-DMAC7.html)
IL (1) IL311450A (cg-RX-API-DMAC7.html)
MX (1) MX2024003262A (cg-RX-API-DMAC7.html)
TW (1) TW202330916A (cg-RX-API-DMAC7.html)
WO (1) WO2023044006A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202402511B (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021236952A1 (en) * 2020-05-20 2021-11-25 Flagship Pioneering, Inc. Compositions and methods for producing human polyclonal antibodies
IL312965A (en) * 2021-11-24 2024-07-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and their uses
WO2024102799A1 (en) * 2022-11-08 2024-05-16 Flagship Pioneering Innovations Vi, Llc Compositions and methods for producing circular polyribonucleotides
EP4648794A2 (en) 2023-01-09 2025-11-19 Flagship Pioneering Innovations VII, LLC Vaccines and related methods
TW202438515A (zh) 2023-02-06 2024-10-01 美商旗艦先鋒創新有限責任(Vii)公司 免疫調節組合物及相關方法
EP4680750A1 (en) * 2023-03-15 2026-01-21 Flagship Pioneering Innovations VI, LLC Compositions comprising polyribonucleotides and uses thereof
EP4698150A1 (en) 2023-04-19 2026-02-25 Sail Biomedicines, Inc. Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids
WO2024220752A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Rna therapeutic compositions
WO2024220712A2 (en) 2023-04-19 2024-10-24 Sail Biomedicines, Inc. Vaccine compositions
WO2024233308A2 (en) * 2023-05-05 2024-11-14 Orna Therapeutics, Inc. Circular rna compositions and methods
GB202308675D0 (en) * 2023-06-09 2023-07-26 Res & Innovation Uk Circular rnas and methods for making the same
CN117603988B (zh) * 2023-11-08 2026-04-21 国际竹藤中心 金镶玉竹环状RNA PacircCNGC及其应用
WO2025106930A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof
WO2025106915A1 (en) 2023-11-17 2025-05-22 Sail Biomedicines, Inc. Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof
CN122249557A (zh) * 2023-11-23 2026-06-19 上海圆因生物科技有限公司 编码fgf21的环状rna及其用途
WO2025147583A1 (en) 2024-01-05 2025-07-10 Sail Biomedicines, Inc. Engineered pd-1 ligands
US20250375499A1 (en) 2024-01-26 2025-12-11 Flagship Pioneering Innovations Vii, Llc Immunoreceptor inhibitory proteins and related methods
WO2025179198A1 (en) 2024-02-23 2025-08-28 Sail Biomedicines, Inc. Circular polyribonucleotides and unmodified linear rnas with reduced immunogenicity
TW202613158A (zh) 2024-05-16 2026-04-01 美商旗艦先鋒創新有限責任(Vii)公司 免疫受體抑制蛋白及相關方法
WO2025245111A1 (en) 2024-05-22 2025-11-27 Flagship Pioneering Innovations Vii, Llc Immunoreceptor targeting proteins and related methods
WO2025252998A2 (en) * 2024-06-07 2025-12-11 RNAvate Limited Materials and methods for making circular rnas
WO2025259931A1 (en) * 2024-06-14 2025-12-18 Orbital Therapeutics, Inc. Compositions and methods for rna circularization
WO2026092609A1 (en) * 2024-11-01 2026-05-07 Kudo Biotechnology, Inc. Circrna production method
WO2026122747A2 (en) 2024-12-05 2026-06-11 Flagship Pioneering Innovations Vii, Llc Novel immunomodulatory proteins and related methods
WO2026148005A1 (en) 2025-01-03 2026-07-09 Sail Biomedicines, Inc. Compositions and methods for purifying polyribonucleotides
WO2026152164A1 (en) 2025-01-13 2026-07-16 Sail Biomedicines, Inc. Cd5-targeted lipid nanoparticles encapsulating polyribonucleotides encoding chimeric antigen receptors, and methods to generate car-expressing t cells in vivo

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US99823A (en) 1870-02-15 Improved indigo soap
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5766903A (en) 1995-08-23 1998-06-16 University Technology Corporation Circular RNA and uses thereof
US5849727A (en) 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6693086B1 (en) 1998-06-25 2004-02-17 National Jewish Medical And Research Center Systemic immune activation method using nucleic acid-lipid complexes
WO2002087541A1 (en) 2001-04-30 2002-11-07 Protiva Biotherapeutics Inc. Lipid-based formulations for gene transfer
CN1882693B (zh) 2003-09-15 2012-08-15 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用
JP4380411B2 (ja) 2004-04-30 2009-12-09 澁谷工業株式会社 滅菌方法
BRPI0519468A2 (pt) 2004-12-27 2009-01-27 Silence Therapeutics Ag complexos de lipÍdeos revestido e seu uso
US7404969B2 (en) 2005-02-14 2008-07-29 Sirna Therapeutics, Inc. Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules
US7451428B2 (en) 2005-02-24 2008-11-11 Texas Instruments Incorporated Merging sub-resolution assist features of a photolithographic mask through the use of a merge bar
DE112007000074T5 (de) 2006-07-10 2009-04-02 Memsic Inc., Andover System zum Erfassen einer Gierrate unter Verwendung eines Magnetfeldsensors sowie tragbare elektronische Vorrichtungen unter Verwendung hiervon
EP3100718B1 (en) 2008-01-02 2019-11-27 Arbutus Biopharma Corporation Improved compositions and methods for the delivery of nucleic acids
EP2279254B1 (en) 2008-04-15 2017-07-05 Protiva Biotherapeutics Inc. Novel lipid formulations for nucleic acid delivery
WO2009132131A1 (en) 2008-04-22 2009-10-29 Alnylam Pharmaceuticals, Inc. Amino lipid based improved lipid formulation
US20120128767A1 (en) 2008-05-01 2012-05-24 Lee William W Therapeutic calcium phosphate particles and methods of making and using same
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
EP2937418B1 (en) 2008-10-20 2017-10-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
EP3699172A3 (en) 2008-11-10 2020-11-18 Arbutus Biopharma Corporation Novel lipids and compositions for the delivery of therapeutics
WO2010054384A1 (en) 2008-11-10 2010-05-14 Alnylam Pharmaceuticals, Inc. Lipids and compositions for the delivery of therapeutics
WO2010084371A1 (en) * 2009-01-26 2010-07-29 Mitoprod Novel circular interfering rna molecules
KR20220038506A (ko) 2009-06-10 2022-03-28 알닐람 파마슈티칼스 인코포레이티드 향상된 지질 조성물
ES2613498T3 (es) 2009-07-01 2017-05-24 Protiva Biotherapeutics Inc. Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9181295B2 (en) 2009-08-20 2015-11-10 Sirna Therapeutics, Inc. Cationic lipids with various head groups for oligonucleotide delivery
WO2011066651A1 (en) 2009-12-01 2011-06-09 Protiva Biotherapeutics, Inc. Snalp formulations containing antioxidants
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
US20130116419A1 (en) 2010-01-22 2013-05-09 Daniel Zewge Post-synthetic chemical modification of rna at the 2'-position of the ribose ring via "click" chemistry
US20120315324A1 (en) 2010-02-05 2012-12-13 University Of Louisville Research Foundation, Inc. Exosomal compositions and methods for the treatment of disease
US20130123338A1 (en) 2010-05-12 2013-05-16 Protiva Biotherapeutics, Inc. Novel cationic lipids and methods of use thereof
US10077232B2 (en) 2010-05-12 2018-09-18 Arbutus Biopharma Corporation Cyclic cationic lipids and methods of use
EP4481047A3 (en) 2010-06-03 2025-04-16 Alnylam Pharmaceuticals, Inc. Biodegradable lipids for the delivery of active agents
DK2575767T3 (en) 2010-06-04 2017-03-13 Sirna Therapeutics Inc HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
WO2012016184A2 (en) 2010-07-30 2012-02-02 Alnylam Pharmaceuticals, Inc. Methods and compositions for delivery of active agents
EP3542789A3 (en) 2010-08-31 2020-01-01 GlaxoSmithKline Biologicals SA Lipids suitable for liposomal delivery of protein-coding rna
ES2987915T3 (es) 2010-09-20 2024-11-18 Sirna Therapeutics Inc Nuevos lípidos catiónicos de bajo peso molecular para el suministro de oligonucleótidos
EP2621480B1 (en) 2010-09-30 2018-08-15 Sirna Therapeutics, Inc. Low molecular weight cationic lipids for oligonucleotide delivery
US20120101478A1 (en) 2010-10-21 2012-04-26 Allergan, Inc. Dual Cartridge Mixer Syringe
WO2012054365A2 (en) 2010-10-21 2012-04-26 Merck Sharp & Dohme Corp. Novel low molecular weight cationic lipids for oligonucleotide delivery
EP2638036B1 (en) 2010-11-09 2017-08-16 Betta Pharmaceuticals Co., Ltd. Compound for increasing kinase active and application thereof
US9617461B2 (en) 2010-12-06 2017-04-11 Schlumberger Technology Corporation Compositions and methods for well completions
US9999673B2 (en) 2011-01-11 2018-06-19 Alnylam Pharmaceuticals, Inc. PEGylated lipids and their use for drug delivery
WO2012162210A1 (en) 2011-05-26 2012-11-29 Merck Sharp & Dohme Corp. Ring constrained cationic lipids for oligonucleotide delivery
WO2013016058A1 (en) 2011-07-22 2013-01-31 Merck Sharp & Dohme Corp. Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery
JP6250543B2 (ja) 2011-09-27 2017-12-20 アルニラム・ファーマシューティカルズ・インコーポレーテッド ジ脂肪族置換peg化脂質
US9512073B2 (en) 2011-10-27 2016-12-06 Massachusetts Institute Of Technology Amino acid-, peptide-and polypeptide-lipids, isomers, compositions, and uses thereof
WO2013070324A1 (en) 2011-11-07 2013-05-16 University Of Louisville Research Foundation, Inc. Edible plant-derived microvesicle compositions for diagnosis and treatment of disease
WO2013073480A1 (ja) 2011-11-18 2013-05-23 日油株式会社 細胞内動態を改善したカチオン性脂質
WO2013086322A1 (en) 2011-12-07 2013-06-13 Alnylam Pharmaceuticals, Inc. Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents
US20140308304A1 (en) 2011-12-07 2014-10-16 Alnylam Pharmaceuticals, Inc. Lipids for the delivery of active agents
DE21212055T1 (de) 2011-12-07 2022-08-04 Alnylam Pharmaceuticals, Inc. Biologisch abbaubare lipide zur freisetzung von wirkstoffen
JP6182457B2 (ja) 2011-12-12 2017-08-16 協和発酵キリン株式会社 カチオン性脂質を含有するドラックデリバリーシステムのための脂質ナノ粒子
WO2013116126A1 (en) 2012-02-01 2013-08-08 Merck Sharp & Dohme Corp. Novel low molecular weight, biodegradable cationic lipids for oligonucleotide delivery
US9352042B2 (en) 2012-02-24 2016-05-31 Protiva Biotherapeutics, Inc. Trialkyl cationic lipids and methods of use thereof
CA2867323C (en) 2012-03-27 2020-07-07 Sirna Therapeutics, Inc. Diether based biodegradable cationic lipids for sirna delivery
ES2887254T3 (es) 2013-03-08 2021-12-22 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
ES2746803T3 (es) * 2013-05-15 2020-03-06 Robert Kruse Traducción intracelular de ARN circular
WO2015011633A1 (en) 2013-07-23 2015-01-29 Protiva Biotherapeutics, Inc. Compositions and methods for delivering messenger rna
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
ES3032935T3 (en) 2013-10-22 2025-07-29 Translate Bio Inc Lipid formulations for delivery of messenger rna
BR112016011195A2 (pt) 2013-11-18 2017-09-19 Rubius Therapeutics Inc Células eritroides enucleadas e seus métodos de fabricação, composição farmacêutica e seu uso, uso de uma população de células eritroides, biorreator, mistura de células e dispositivo médico
CN110003066B (zh) 2013-11-18 2021-09-03 阿克丘勒斯治疗公司 用于rna递送的可电离的阳离子脂质
US9365610B2 (en) 2013-11-18 2016-06-14 Arcturus Therapeutics, Inc. Asymmetric ionizable cationic lipid for RNA delivery
US10059655B2 (en) 2013-12-19 2018-08-28 Novartis Ag Lipids and lipid compositions for the delivery of active agents
US10426737B2 (en) 2013-12-19 2019-10-01 Novartis Ag Lipids and lipid compositions for the delivery of active agents
CN106456744A (zh) 2014-04-01 2017-02-22 鲁比厄斯治疗法股份有限公司 用于免疫调节的方法和组合物
CA2953341C (en) 2014-06-25 2023-01-24 Acuitas Therapeutics Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
AU2015289656A1 (en) 2014-07-16 2017-02-16 Modernatx, Inc. Circular polynucleotides
WO2016183482A1 (en) 2015-05-13 2016-11-17 Rubius Therapeutics, Inc. Membrane-receiver complex therapeutics
EP3303377B1 (en) 2015-06-05 2022-11-23 Dana-Farber Cancer Institute, Inc. Compositions and methods for transient gene therapy with enhanced stability
RS64331B1 (sr) 2015-06-19 2023-08-31 Massachusetts Inst Technology Alkenil supstituisani 2,5-piperazindioni i njihova primena u sastavima za isporuku agensa u organizam ili ćeliju subjekta
HUE067372T2 (hu) 2015-06-29 2024-10-28 Acuitas Therapeutics Inc Lipidek és nanoszemcsés lipid formulázások nukleinsavak beadására
CN107920995A (zh) 2015-07-02 2018-04-17 路易斯威尔大学研究基金会 用于递送miRNA的源自可食用植物的微囊泡组合物和用于治疗癌症的方法
HRP20220156T1 (hr) 2015-09-17 2022-04-15 Modernatx, Inc. Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
CN108368028B (zh) 2015-10-28 2021-09-03 爱康泰生治疗公司 用于递送核酸的新型脂质和脂质纳米颗粒制剂
WO2018081480A1 (en) 2016-10-26 2018-05-03 Acuitas Therapeutics, Inc. Lipid nanoparticle formulations
DK3386484T3 (da) 2015-12-10 2022-07-04 Modernatx Inc Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
US12678515B2 (en) 2015-12-30 2026-07-14 Acuitas Therapeutics, Inc. Lipids and lipid nanoparticle formulations for delivery of nucleic acids
CN108697733A (zh) 2016-01-11 2018-10-23 鲁比厄斯治疗法股份有限公司 与癌症适应症的多模式治疗性细胞体系有关的组合物和方法
ES3030658T3 (en) 2016-03-30 2025-07-01 Intellia Therapeutics Inc Lipid nanoparticle formulations for crispr/cas components
MX2019000205A (es) 2016-07-07 2019-09-23 Rubius Therapeutics Inc Composiciones y metodos relacionados con sistemas celulares terapeuticos que expresan arn exogeno.
BR112019011138A2 (pt) 2016-12-02 2019-10-01 Rubius Therapeutics, Inc. composições e métodos relacionados com sistemas celulares para penetração em tumores sólidos
CN110520522A (zh) 2017-02-17 2019-11-29 鲁比厄斯治疗法股份有限公司 功能化红系细胞
US11576872B2 (en) 2017-05-08 2023-02-14 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
EP3679148A4 (en) 2017-09-08 2021-06-09 Generation Bio Co. LIPID NANOPARTICLE FORMULATIONS FROM NONVIRAL, CAPSID-FREE DNA VECTORS
IL311278B2 (en) 2017-09-29 2026-05-01 Intellia Therapeutics Inc Polynucleotides, compositions, and methods for genome editing
EP3688162B1 (en) 2017-09-29 2024-03-06 Intellia Therapeutics, Inc. Formulations
MX2020006150A (es) 2017-12-15 2020-11-11 Flagship Pioneering Innovations Vi Llc Composiciones que comprenden polirribonucleotidos circulares y usos de las mismas.
KR102959497B1 (ko) 2018-05-11 2026-05-04 빔 테라퓨틱스, 인크. 프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 돌연변이를 억제하는 방법
CN112399860B (zh) 2018-06-06 2024-08-16 麻省理工学院 用于在真核细胞中翻译的环状rna
KR102950624B1 (ko) 2018-07-24 2026-04-10 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 원형 폴리리보뉴클레오티드를 포함하는 조성물 및 이의 용도
AR116016A1 (es) 2018-08-24 2021-03-25 Flagship Pioneering Innovations Vi Llc Métodos para fabricar paquetes mensajeros vegetales
AU2019327449B2 (en) 2018-08-28 2026-04-09 Flagship Pioneering Innovations Vi, Llc Methods and compositions for modulating a genome
US12090235B2 (en) 2018-09-20 2024-09-17 Modernatx, Inc. Preparation of lipid nanoparticles and methods of administration thereof
CA3116576A1 (en) 2018-10-18 2020-04-23 Acuitas Therapeutics, Inc. Lipids for lipid nanoparticle delivery of active agents
AU2019384557B2 (en) 2018-11-21 2025-07-17 Translate Bio, Inc. Treatment of cystic fibrosis by delivery of nebulized mRNA encoding CFTR
MA55082A (fr) 2019-03-01 2022-01-05 Flagship Pioneering Innovations Vi Llc Compositions, procédés, et kits pour l'administration de polyribonucléotides
KR102901623B1 (ko) 2019-03-01 2025-12-18 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 폴리리보뉴클레오티드 및 이의 미용적 용도
CN121081491A (zh) * 2019-03-04 2025-12-09 旗舰创业创新第六有限责任公司 环状多核糖核苷酸及其药物组合物
CN115806976A (zh) 2019-03-20 2023-03-17 中国科学院上海营养与健康研究所 利用环形rna进行蛋白翻译及其应用
JP7618577B2 (ja) 2019-03-25 2025-01-21 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 修飾環状ポリリボヌクレオチドを含む組成物及びその使用
WO2020219876A1 (en) 2019-04-25 2020-10-29 Intellia Therapeutics, Inc. Ionizable amine lipids and lipid nanoparticles
JP7686574B2 (ja) 2019-05-22 2025-06-02 マサチューセッツ インスティテュート オブ テクノロジー 環状rna組成物及び方法
US20220257794A1 (en) 2019-06-14 2022-08-18 Flagship Pioneering Innovations Vi, Llc Circular rnas for cellular therapy
AU2020296190A1 (en) 2019-06-19 2022-01-06 Flagship Pioneering Innovations Vi, Llc Methods of dosing circular polyribonucleotides
US12636369B2 (en) 2019-06-19 2026-05-26 Flagship Pioneering Innovations Vi, Llc Compositions comprising circular polyribonucleotides for protein modulation and uses thereof
US20220288176A1 (en) 2019-08-28 2022-09-15 The Board Of Trustees Of The Leland Stanford Junior University Circular rna modification and methods of use
MX2022006854A (es) 2019-12-04 2022-11-30 Orna Therapeutics Inc Composiciones y metodos de arn circular.
AU2021216593A1 (en) 2020-02-04 2022-08-25 Duke University Compositions and methods for circular RNA expression
CN116322788A (zh) 2020-05-19 2023-06-23 奥纳治疗公司 环状rna组合物和方法
AU2021275223A1 (en) 2020-05-20 2023-02-02 Flagship Pioneering Innovations Vi, Llc. Coronavirus antigen compositions and their uses
IL298363A (en) 2020-05-20 2023-01-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
CN116635525A (zh) 2020-08-21 2023-08-22 北京大学 环状rna疫苗及其使用方法
IL300947A (en) 2020-09-03 2023-04-01 Flagship Pioneering Innovations Vi Llc Immunogenic compositions and uses thereof
EP4341423A1 (en) 2021-05-18 2024-03-27 Flagship Pioneering Innovations VI, LLC Methods of enriching for circular polyribonucleotides
JP2024521304A (ja) 2021-05-18 2024-05-31 フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー 環状ポリリボヌクレオチドを濃縮する方法
CN115404240A (zh) 2021-05-28 2022-11-29 上海环码生物医药有限公司 制备环形rna的构建体、方法及其用途
AU2022288705A1 (en) 2021-06-10 2023-12-07 Orna Therapeutics, Inc. Circular rna compositions and methods
KR20240047986A (ko) 2021-07-27 2024-04-12 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 가공을 위한 디바이스, 시스템 및 방법

Also Published As

Publication number Publication date
US12338474B2 (en) 2025-06-24
AU2022346861A1 (en) 2024-03-28
US20230212629A1 (en) 2023-07-06
CN118234867A (zh) 2024-06-21
US20250277224A1 (en) 2025-09-04
CA3232635A1 (en) 2023-03-23
JP2024534428A (ja) 2024-09-20
EP4464783A2 (en) 2024-11-20
ES2994006T3 (en) 2025-01-16
ZA202402511B (en) 2024-12-18
EP4464783A3 (en) 2025-01-22
AR127073A1 (es) 2023-12-13
TW202330916A (zh) 2023-08-01
EP4271818A1 (en) 2023-11-08
WO2023044006A1 (en) 2023-03-23
EP4271818B1 (en) 2024-07-31
WO2023044006A8 (en) 2023-04-27
KR20240099185A (ko) 2024-06-28
DK4271818T3 (da) 2024-11-04
IL311450A (en) 2024-05-01

Similar Documents

Publication Publication Date Title
ZA202402511B (en) Compositions and methods for producing circular polyribonucleotides
MX2023012659A (es) Composiciones y metodos para secuenciación por síntesis.
MX2023004157A (es) Composiciones de oligosacaridos para el uso como alimento para animales y sus metodos para producirlas.
MY194798A (en) Novel adenylosuccinate synthetase and method for producing purine nucleotides using the same
PH12019502171A1 (en) Composition and methods for immunooncology
ZA201804654B (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
MX2021010827A (es) Materiales funcionales de origen vegetal.
PH12020550132A1 (en) Novel enantiomers of a series of antiviral compounds
BR112015013822A2 (pt) método de vaso único para a síntese de cu-ssz-13, o composto obtido através do método e utilização do mesmo
EA201070605A8 (ru) Применение бактерий для производства биоэнергии
MX2024007870A (es) Polirribonucleotidos circulares que codifican polipeptidos antifusogenicos.
UA105785C2 (uk) Спосіб очищення ліпопептидів
GT200600224A (es) Metodos para purificar tigeciclina
GB2548740A (en) Methods for generation of podocytes from pluripotent stem cells and cells produced by the same
MX2020012589A (es) Anticuerpos anti-tmeff2 monoespecificos y multiespecificos y sus usos.
MX2020011986A (es) Composiciones que comprenden glucosa y hemicelulosa y su uso.
ZA202002456B (en) Zeolite synthesis in a reactor with controlled velocity profile
IN2014MU01231A (cg-RX-API-DMAC7.html)
ZA202211168B (en) Fragrance composition
MX2024004833A (es) Procedimiento para producir rebaudiosido d y rebaudiosido m.
ZA202401405B (en) Compositions and methods for anti-pacap antibodies
MX2021011287A (es) Variantes de alfa-amilasa y polinucleotidos que codifican las mismas.
EA202091834A1 (ru) Непрерывный способ получения тразодона
TW200621990A (en) Process for producing polysaccharide K5
MX2017014890A (es) Metodos de produccion de acetolactato-descarboxilasa (aldc).